News
Opinion
9hOpinion
Zacks Investment Research on MSNTop Analyst Reports for Eli Lilly, Home Depot & SAPThe Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), The Home ...
Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.
The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...
Eli Lilly & Co. and health tech company Kalderos Inc. are seeking to revive lawsuits in the DC Circuit after a federal judge ...
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...
For stroke survivors, talking therapy is associated with moderate reductions in depression and large reductions in anxiety ...
Explore more
Novo Nordisk's shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe's largest by market capitalization. Novo Nordisk's ADR (NVO) (DK:NOVO.B), at ...
Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...
Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.
Eli Lilly has delivered a jaw-dropping 635% stock price increase from 2020 to 2024, driven by high hopes and heavyweight drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results